ID   PC-346C
AC   CVCL_4883
SY   PC346C
DR   BTO; BTO:0002831
DR   GEO; GSM539100
DR   GEO; GSM539101
DR   GEO; GSM539102
DR   GEO; GSM539103
DR   GEO; GSM539104
DR   GEO; GSM539105
DR   GEO; GSM539106
DR   GEO; GSM539107
DR   GEO; GSM539108
DR   GEO; GSM539109
DR   GEO; GSM539110
DR   GEO; GSM539111
DR   GEO; GSM1374819
DR   IARC_TP53; 21087
DR   Wikidata; Q54938432
RX   CelloPub=CLPUB00698;
RX   CelloPub=CLPUB00699;
RX   PubMed=11304728;
RX   PubMed=14518029;
RX   PubMed=14518030;
RX   PubMed=15900601;
RX   PubMed=20976069;
CC   Characteristics: Established from the PC-346 xenograft (CelloPub=CLPUB00699).
CC   Characteristics: Optimal proliferation of the cell line requires androgens and is inhibited by the antiandrogen hydroxyflutamide.
CC   Doubling time: 4-5 days (CelloPub=CLPUB00699).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14518029).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): PubMed=11304728; PubMed=14518029
ST   Amelogenin: X (PubMed=14518029_clone_2)
ST   Amelogenin: X,Y (PubMed=11304728; PubMed=14518029_clone_1)
ST   D13S317: 14
ST   D18S51: 12,13
ST   D21S11: 29,34.2
ST   D3S1358: 16,18 (PubMed=11304728; PubMed=14518029_clone_1)
ST   D3S1358: 16,19 (PubMed=14518029_clone_2)
ST   D5S818: 12,14
ST   D7S820: 7,12
ST   D8S1179: 13,14
ST   FGA: 19,24
ST   vWA: 18,19 (PubMed=11304728; PubMed=14518029_clone_1)
ST   vWA: 19 (PubMed=14518029_clone_2)
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4882 ! PC-346
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 16
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands.
//
RX   CelloPub=CLPUB00699;
RA   Romijn J.C., Erkens-Schulze S., van Weerden W.M., Teubel W.J.,
RA   Trapman J., Schroder F.H.;
RT   "Development and characterization of a new in vitro model to study the
RT   mechanisms of prostate cancer progression.";
RL   Urol. Res. 23:265.P81-265.P81(1995).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=14518029; DOI=10.1002/pros.10290;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U.,
RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;
RT   "Molecular characterization of human prostate carcinoma cell lines.";
RL   Prostate 57:205-225(2003).
//
RX   PubMed=14518030; DOI=10.1002/pros.10291;
RA   van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S.,
RA   Nordeen S.K., Miller G.J., Varella-Garcia M.;
RT   "Spectral karyotype (SKY) analysis of human prostate carcinoma cell
RT   lines.";
RL   Prostate 57:226-244(2003).
//
RX   PubMed=15900601; DOI=10.1002/ijc.21201;
RA   Marques R.B., Erkens-Schulze S., de Ridder C.M.A., Hermans K.G.,
RA   Waltering K., Visakorpi T., Trapman J., Romijn J.C., van Weerden W.M.,
RA   Jenster G.;
RT   "Androgen receptor modifications in prostate cancer cells upon
RT   long-term androgen ablation and antiandrogen treatment.";
RL   Int. J. Cancer 117:221-229(2005).
//
RX   PubMed=20976069; DOI=10.1371/journal.pone.0013500; PMCID=PMC2957443;
RA   Marques R.B., Dits N.F., Erkens-Schulze S., van Weerden W.M.,
RA   Jenster G.;
RT   "Bypass mechanisms of the androgen receptor pathway in
RT   therapy-resistant prostate cancer cell models.";
RL   PLoS ONE 5:E13500-E13500(2010).
//